A Phase 2 interventional study of Lenvatinib in Relapsed or Refractory Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Completed at 49 sites in 20 countries. Open to participants aged 2 Years to 21 Years. Per ClinicalTrials.gov, last updated 2025-10-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the antitumor activity and safety of lenvatinib (MK-7902/E7080) in children, adolescents, and young adults with relapsed or refractory solid malignancies after administration. Participants were enrolled into Ewing sarcoma (EWS), rhabdomyosarcoma (RMS), high-grade glioma (HGG), diffuse midline glioma, medulloblastoma, ependymoma, and Other Solid Tumors Excluding Osteosarcoma, diffuse midline glioma, medulloblastoma, and ependymoma cohorts.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Ewing sarcoma will receive lenvatinib 14 mg/m\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with rhabdomyosarcoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with high grade glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with diffuse midline glioma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with medulloblastoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with ependymoma will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Participants with other solid tumors will receive lenvatinib 14 mg/m\^2 QD orally until progressive disease or unacceptable toxicity.
Drug: Lenvatinib
Lenvatinib capsules administered orally at 14 mg/m\^2 QD
Also known as: MK-7902, E7080, LENVIMA
Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment
ORR at Week 16 was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1 at 16 Weeks. For participants with HGG, response was assessed according to RANO criteria whereby overall response is based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
Time frame: Up to 16 weeks
ORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment
ORR was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1. For participants with HGG, response was assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
Time frame: Up to approximately 21 months
Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
PFS was defined as the time from the date of the first administration of study drug until the date of first documentation of progressive disease (PD) per RECIST 1.1 or RANO (for HGG) or death (whichever occurs first).
Time frame: Up to approximately 21 months
Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
BOR is defined as the participant's best confirmed response (CR or PR) over the treatment period as assessed by the investigator per RECIST 1.1 or RANO. As per RECIST 1.1, CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
Time frame: Up to approximately 21 months
Duration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
DOR was defined as the time from the date of the first documented CR or PR to the date first documentation of progressive disease or death (whichever occurs first). As per RECIST 1.1, CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
Time frame: Up to approximately 21 months
Disease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
DCR was defined as a BOR of CR or PR, or stable disease (SD). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD should be ≥7 weeks. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.
Time frame: Up to approximately 21 months
Clinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment
CBR was defined as a BOR of CR or PR, or durable SD (Duration of SD should be ≥23 weeks since the first dose of the study treatment. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response is assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.
Time frame: Up to approximately 21 months
Number of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.
Time frame: Up to approximately 50 months
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported.
Time frame: Up to approximately 38 months
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Taste Category
A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the supplemental Statistical Analysis Plan (sSAP), all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the taste category is presented.
Time frame: Cycle 1 Day 1 (cycle = 28 days)
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Appearance Category
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the appearance category is presented.
Time frame: Cycle 1 Day 1 (cycle = 28 days)
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Smell Category
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.
Time frame: Cycle 1 Day 1 (cycle = 28 days)
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Mouth Feel Category
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the mouth feel category is presented.
Time frame: Cycle 1 Day 1 (cycle = 28 days)
Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Overall Acceptability Category
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the overall acceptability category is presented.
Time frame: Cycle 1 Day 1 (cycle = 28 days)
Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss)
Blood samples were taken predose and at specified times postdose on Days 1-28 to determine the AUCss of Lenvatinib.
Time frame: Cycle 1 Day 1 (0.5-4 and 6-10 hours post-dose), Cycle 1 Day 15 (pre-dose, 0.5-4, and 6-10 hours post-dose), and Cycle 2 Day 1 (pre-dose and 2-12 hours post-dose). A cycle is 28 days.
Participants were recruited to tumor cohorts of Ewing Sarcoma, Rhabdomyosarcoma, High Grade Glioma, and Other Solid Tumors Excluding Osteosarcoma. Enrollment to the protocol pre-specified tumor cohort of "Other Solid Tumors Excluding Osteosarcoma" was further expanded into categories of Diffuse midline glioma, Medulloblastoma, and Ependymoma.
| Milestone | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Started | 9 | 17 | 8 | 9 | 9 | 9 | 66 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 9 | 17 | 8 | 9 | 9 | 9 | 66 |
| Withdrew: Death | 9 | 16 | 8 | 9 | 8 | 9 | 55 |
| Withdrew: Withdrawal by parent/guardian | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 1 | 0 | 10 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
ORR at Week 16 was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1 at 16 Weeks. For participants with HGG, response was assessed according to RANO criteria whereby overall response is based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \[SPD\] decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
| Percentage of Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) At Week 16 Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) or Response Assessment in Neuro-Oncology (RANO) Criteria (for High Grade Glioma [HGG] Only), by Investigator Assessment | 22.2 (2.8 to 60.0) | 11.8 (1.5 to 36.4) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 7.7 (2.5 to 17.0) |
ORR was defined as the percentage of participants with a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD) as assessed by the investigator per RECIST 1.1. For participants with HGG, response was assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
| Percentage of Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| ORR Per RECIST 1.1 or RANO Criteria (for HGG Only), by Investigator Assessment | 22.2 (2.8 to 60.0) | 11.8 (1.5 to 36.4) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 7.7 (2.5 to 17.0) |
PFS was defined as the time from the date of the first administration of study drug until the date of first documentation of progressive disease (PD) per RECIST 1.1 or RANO (for HGG) or death (whichever occurs first).
| Months | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment | 3.0 (0.3 to 9.3) | 2.6 (1.2 to 5.6) | 1.9 (1.4 to NA) | 1.8 (0.5 to 4.9) | 3.4 (0.5 to 8.5) | 2.5 (1.2 to 7.4) | 3.8 (3.2 to 5.7) |
BOR is defined as the participant's best confirmed response (CR or PR) over the treatment period as assessed by the investigator per RECIST 1.1 or RANO. As per RECIST 1.1, CR is defined as disappearance of all target lesions and PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
| Percentage of Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Best Overall Response (BOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment | 22.2 (2.8 to 60.0) | 11.8 (1.5 to 36.4) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 33.6) | 7.7 (2.5 to 17.0) |
DOR was defined as the time from the date of the first documented CR or PR to the date first documentation of progressive disease or death (whichever occurs first). As per RECIST 1.1, CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. For participants with HGG, response will be assessed according to RANO criteria whereby overall RANO response is based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value) and clinical performance status with steroid dose information.
| Months | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment | NA (5.7 to NA) | 4.6 (3.7 to NA) | — | — | — | — | 4.6 (3.7 to NA) |
DCR was defined as a BOR of CR or PR, or stable disease (SD). To be assigned a BOR of SD, the time from the first administration of study drug until the date of documented SD should be ≥7 weeks. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.
| Percentage of Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment | 66.7 (29.9 to 92.5) | 52.9 (27.8 to 77.0) | 33.3 (4.3 to 77.7) | 22.2 (2.8 to 60.0) | 55.6 (21.2 to 86.3) | 55.6 (21.2 to 86.3) | 64.6 (51.8 to 76.1) |
CBR was defined as a BOR of CR or PR, or durable SD (Duration of SD should be ≥23 weeks since the first dose of the study treatment. As per RECIST 1.1, CR was defined as disappearance of all target lesions, PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For participants with HGG, response is assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: SPD decreased by ≥ 50% from baseline value and SD: SPD \<50% decreased from baseline, but \<25% increased from nadir) and clinical performance status with steroid dose information.
| Percentage of Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) Per RECIST 1.1 or RANO (for HGG Only), by Investigator Assessment | 33.3 (7.5 to 70.1) | 29.4 (10.3 to 56.0) | 0.0 (0.0 to 45.9) | 11.1 (0.3 to 48.2) | 44.4 (13.7 to 78.8) | 33.3 (7.5 to 70.1) | 40.0 (28.0 to 52.9) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced at least one AE is reported.
| Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 9 | 17 | 8 | 9 | 9 | 8 | 66 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported.
| Participants | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 1 | 0 | 0 | 0 | 1 | 2 | 6 |
A hedonic Visual Analog Scale (VAS) was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the supplemental Statistical Analysis Plan (sSAP), all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the taste category is presented.
| Participants | All Tumor Types |
|---|---|
| Super Bad | 1 |
| Really Bad | 0 |
| Bad | 2 |
| Maybe Good or Maybe Bad | 5 |
| Good | 1 |
| Really Good | 0 |
| Super Good | 1 |
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the appearance category is presented.
| Participants | All Tumor Types |
|---|---|
| Super Bad | 0 |
| Really Bad | 0 |
| Bad | 1 |
| Maybe Good or Maybe Bad | 5 |
| Good | 2 |
| Really Good | 0 |
| Super Good | 2 |
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the smell category is presented.
| Participants | All Tumor Types |
|---|---|
| Super Bad | 0 |
| Really Bad | 0 |
| Bad | 0 |
| Maybe Good or Maybe Bad | 8 |
| Good | 1 |
| Really Good | 0 |
| Super Good | 1 |
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the mouth feel category is presented.
| Participants | All Tumor Types |
|---|---|
| Super Bad | 0 |
| Really Bad | 1 |
| Bad | 2 |
| Maybe Good or Maybe Bad | 4 |
| Good | 1 |
| Really Good | 2 |
| Super Good | 0 |
A hedonic VAS was used to assess taste likability or "palatability" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the overall acceptability category is presented.
| Participants | All Tumor Types |
|---|---|
| Super Bad | 0 |
| Really Bad | 1 |
| Bad | 1 |
| Maybe Good or Maybe Bad | 3 |
| Good | 3 |
| Really Good | 1 |
| Super Good | 1 |
Blood samples were taken predose and at specified times postdose on Days 1-28 to determine the AUCss of Lenvatinib.
| ng*hr/ml | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Other Solid Tumors Excluding Osteosarcoma |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve of Lenvatinib at Steady State (AUCss) | 5896 ± 31.2 | 3915 ± 32.9 | 3660 ± 43.5 | 4990 ± 53.2 |
Collected over Up to approximately 50 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ewing Sarcoma | 9/9 (100%) | 4/9 (44.4%) | 9/9 (100%) |
| Rhabdomyosarcoma | 17/17 (100%) | 5/17 (29.4%) | 17/17 (100%) |
| High Grade Glioma | 8/8 (100%) | 6/8 (75%) | 6/8 (75%) |
| Diffuse Midline Glioma | 9/9 (100%) | 4/9 (44.4%) | 9/9 (100%) |
| Medulloblastoma | 8/9 (88.9%) | 4/9 (44.4%) | 9/9 (100%) |
| Ependymoma | 9/9 (100%) | 4/9 (44.4%) | 7/9 (77.8%) |
| Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma | 55/66 (83.3%) | 39/66 (59.1%) | 66/66 (100%) |
| Event | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| Pneumonia aspirationInfections and infestations | 0/9 | 0/17 | 0/8 | 2/9 | 0/9 | 0/9 | 1/66 |
| PneumoniaInfections and infestations | 0/9 | 0/17 | 1/8 | 0/9 | 0/9 | 0/9 | 0/66 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/9 | 0/17 | 1/8 | 0/9 | 0/9 | 0/9 | 0/66 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/9 | 0/17 | 1/8 | 0/9 | 0/9 | 0/9 | 0/66 |
| HemiparesisNervous system disorders | 0/9 | 0/17 | 1/8 | 0/9 | 0/9 | 0/9 | 0/66 |
| Intracranial pressure increasedNervous system disorders | 0/9 | 0/17 | 1/8 | 0/9 | 0/9 | 1/9 | 1/66 |
| HypertensionVascular disorders | 0/9 | 0/17 | 1/8 | 0/9 | 1/9 | 0/9 | 1/66 |
| Inappropriate antidiuretic hormone secretionEndocrine disorders | 0/9 | 0/17 | 0/8 | 0/9 | 1/9 | 0/9 | 0/66 |
| Abdominal painGastrointestinal disorders | 1/9 | 0/17 | 0/8 | 0/9 | 1/9 | 0/9 | 3/66 |
| ColitisGastrointestinal disorders | 1/9 | 0/17 | 0/8 | 0/9 | 0/9 | 0/9 | 0/66 |
| Event | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma |
|---|---|---|---|---|---|---|---|
| HypothyroidismEndocrine disorders | 7/9 | 8/17 | 4/8 | 7/9 | 7/9 | 5/9 | 45/66 |
| DiarrhoeaGastrointestinal disorders | 5/9 | 6/17 | 0/8 | 0/9 | 4/9 | 3/9 | 22/66 |
| FatigueGeneral disorders | 1/9 | 1/17 | 1/8 | 1/9 | 5/9 | 0/9 | 13/66 |
| Decreased appetiteMetabolism and nutrition disorders | 5/9 | 7/17 | 2/8 | 3/9 | 3/9 | 1/9 | 18/66 |
| HypertensionVascular disorders | 3/9 | 6/17 | 2/8 | 5/9 | 3/9 | 3/9 | 27/66 |
| VomitingGastrointestinal disorders | 4/9 | 7/17 | 1/8 | 2/9 | 4/9 | 2/9 | 18/66 |
| Urinary tract infectionInfections and infestations | 0/9 | 1/17 | 0/8 | 4/9 | 1/9 | 0/9 | 7/66 |
| Platelet count decreasedInvestigations | 2/9 | 3/17 | 0/8 | 0/9 | 4/9 | 1/9 | 14/66 |
| RashSkin and subcutaneous tissue disorders | 0/9 | 1/17 | 1/8 | 4/9 | 0/9 | 0/9 | 7/66 |
| ProteinuriaRenal and urinary disorders | 2/9 | 5/17 | 0/8 | 3/9 | 2/9 | 1/9 | 28/66 |
| Age, Continuous(Years) | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 14.8 ± 4.0 | 13.1 ± 4.7 | 14.0 ± 3.1 | 10.0 ± 5.2 | 13.2 ± 4.5 | 8.7 ± 5.7 | 13.1 ± 5.6 | 12.7 ± 5.3 |
| Sex: Female, Male(Participants) | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 7 | 4 | 8 | 3 | 4 | 32 | 60 |
| Male | 7 | 10 | 4 | 1 | 6 | 5 | 34 | 67 |
| Ethnicity (NIH/OMB)(Participants) | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 0 | 0 | 1 | 0 | 9 | 13 |
| Not Hispanic or Latino | 5 | 11 | 6 | 4 | 2 | 6 | 43 | 77 |
| Unknown or Not Reported | 3 | 4 | 2 | 5 | 6 | 3 | 14 | 37 |
| Race (NIH/OMB)(Participants) | Ewing Sarcoma | Rhabdomyosarcoma | High Grade Glioma | Diffuse Midline Glioma | Medulloblastoma | Ependymoma | Other Solid Tumors Excluding Osteosarcoma, Diffuse Midline Glioma, Medulloblastoma and Ependymoma | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Asian | 3 | 2 | 1 | 3 | 0 | 0 | 13 | 22 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
| White | 3 | 10 | 4 | 2 | 2 | 7 | 35 | 63 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 4 | 3 | 4 | 6 | 2 | 11 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2020 to primary completion in Sep 2022, 25 months.
Results were first posted in Oct 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib